EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants

Yan-Ou Yang, Xiaohua Gong, Phillip Wang, Xiang Liu, Jay Getsy, Jennifer Sheng, Swamy Yeleswaram, Xuejun Chen, Kevin Rockich

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1553 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Yan-Ou Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Pharmacometrics, Incyte Corporation, Wilmington, DE, USA. Hauptthemen laut MEDLINE: Rifampin, Itraconazole, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inducers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zilurgisertib is an oral, activin receptor‐like kinase 2 (ALK2) inhibitor being developed for the treatment of patients with fibrodysplasia ossificans progressiva. In vitro metabolism studies suggest zilurgisertib is primarily eliminated via cytochrome P450 (CYP) 3A4/5‐mediated metabolism, with an additional contribution from renal excretion. A drug‐drug interaction study was conducted to evaluate the impact of the strong CYP3A inhibitor itraconazole and the strong CYP3A4 inducer rifampin on the pharmacokinetics of zilurgisertib in healthy participants. Participants in Cohort 1 (n = 18) received zilurgisertib 100 mg on Days 1 and 10 and itraconazole 200 mg once daily on Days 6‐13. Participants in Cohort 2 (n = 18) received zilurgisertib 100 mg on Days 1 and 13 and rifampin 600 mg once daily on Days 6‐15. With the concomitant administration of itraconazole, the geometric mean maximum plasma drug concentration (C max ) and area under the concentration‐time curve from time 0 to infinity (AUC 0‐inf ) of zilurgisertib increased by 1.28‐ and 2.13‐fold, respectively. With the concomitant administration of rifampin, there was a 2.27‐ and 4.76‐fold reduction in the geometric mean C max and AUC 0‐inf of zilurgisertib, respectively. No dose‐limiting toxicities occurred in either cohort, and all treatment‐emergent adverse events were Grade 1 in severity. Zilurgisertib dose adjustment may be necessary with concomitant administration of strong CYP3A4 inhibitors, and coadministration of zilurgisertib with strong CYP3A4 inducers is not recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinItraconazoleCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3A InducersHumansMaleDrug InteractionsAdultFemaleHealthy VolunteersYoung AdultAdministration, OralArea Under CurveMiddle AgedCytochrome P-450 CYP3A

Stichwörter der Autor:innen

ALK2 inhibitorCYP3A4drug‐drug interactionfibrodysplasia ossificans progressivapharmacokineticszilurgisertib

Substanzen

RifampinItraconazoleCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3ACYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Pharmacometrics, Incyte Corporation, Wilmington, DE, USA.
  • Department of Bioanalysis, Incyte Corporation, Wilmington, DE, USA.
  • Department of Early Development, Incyte Corporation, Wilmington, DE, USA.

Zitieren

APA

Yang, Y. O., Gong, X., Wang, P., Liu, X., Getsy, J., Sheng, J., Yeleswaram, S., Chen, X., & Rockich, K. (2025). Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1553

Vancouver

Yang YO, Gong X, Wang P, Liu X, Getsy J, Sheng J, et al. Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1553

BibTeX
@article{Yang2025,
  author = {Yang, Yan-Ou and Gong, Xiaohua and Wang, Phillip and Liu, Xiang and Getsy, Jay and Sheng, Jennifer and Yeleswaram, Swamy and Chen, Xuejun and Rockich, Kevin},
  title = {Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1553}
}
Kostenlos starten →